ES2970401T3 - Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza - Google Patents

Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza Download PDF

Info

Publication number
ES2970401T3
ES2970401T3 ES13749329T ES13749329T ES2970401T3 ES 2970401 T3 ES2970401 T3 ES 2970401T3 ES 13749329 T ES13749329 T ES 13749329T ES 13749329 T ES13749329 T ES 13749329T ES 2970401 T3 ES2970401 T3 ES 2970401T3
Authority
ES
Spain
Prior art keywords
viral
cells
patient
das181
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13749329T
Other languages
English (en)
Spanish (es)
Inventor
Ron Moss
Tiejun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Application granted granted Critical
Publication of ES2970401T3 publication Critical patent/ES2970401T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13749329T 2012-02-17 2013-02-19 Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza Active ES2970401T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US201261727627P 2012-11-16 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Publications (1)

Publication Number Publication Date
ES2970401T3 true ES2970401T3 (es) 2024-05-28

Family

ID=48984833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13749329T Active ES2970401T3 (es) 2012-02-17 2013-02-19 Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza

Country Status (9)

Country Link
US (5) US20130280332A1 (https=)
EP (1) EP2841092B1 (https=)
JP (1) JP2015508780A (https=)
CN (2) CN104203267A (https=)
AU (3) AU2013221230A1 (https=)
CA (1) CA2864746A1 (https=)
ES (1) ES2970401T3 (https=)
IL (2) IL234116B (https=)
WO (1) WO2013123521A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
EP3885343A1 (en) 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
EP3215160A4 (en) * 2014-11-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20180177852A1 (en) * 2015-06-08 2018-06-28 Ansun Biopharma, Inc. Treatment of human metapneumovirus
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2017252460B2 (en) 2016-04-22 2021-11-18 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
WO2021108462A1 (en) * 2019-11-25 2021-06-03 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CN1700934B (zh) * 2002-09-06 2011-08-03 菲利普莫里斯美国公司 液体气溶胶制剂和用于制备气溶胶的气溶胶产生装置及方法
WO2004047735A2 (en) 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
KR101501780B1 (ko) * 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物

Also Published As

Publication number Publication date
EP2841092A4 (en) 2015-09-16
IL234116B (en) 2020-03-31
US20250387457A1 (en) 2025-12-25
AU2019226190B2 (en) 2021-10-07
IL273194B (en) 2022-10-01
JP2015508780A (ja) 2015-03-23
CA2864746A1 (en) 2013-08-22
EP2841092B1 (en) 2023-12-06
HK1207975A1 (en) 2016-02-19
AU2017258955A1 (en) 2017-12-14
WO2013123521A1 (en) 2013-08-22
US20130280332A1 (en) 2013-10-24
EP2841092C0 (en) 2023-12-06
AU2013221230A1 (en) 2014-10-02
US20210046165A1 (en) 2021-02-18
IL273194B2 (en) 2023-02-01
AU2019226190A1 (en) 2019-09-26
CN109529026A (zh) 2019-03-29
CN104203267A (zh) 2014-12-10
US20150132274A1 (en) 2015-05-14
US20170151315A1 (en) 2017-06-01
EP2841092A1 (en) 2015-03-04
IL273194A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
ES2970401T3 (es) Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza
ES2979287T3 (es) Tratamiento de infección respiratoria
ES3055494T3 (en) Treatment of respiratory diseases
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
CN111467363A (zh) 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
CN111407754A (zh) 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用
US20240000901A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
WO2021253647A1 (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
JP2016535782A (ja) 被験者の気道への酵素の投与のための組成物及び方法
WO2020109621A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
CN108926707A (zh) Pf4的抗rsv应用
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
CN115843267A (zh) 呼吸道病毒感染的治疗
ES2989089T3 (es) Composición farmacéutica para uso en el tratamiento de enfermedad inducida por virus
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
WO2022166885A1 (en) Recombinant super-compound interferon (rsifn-co) for treating covid-19 patients with or without symptoms
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
EP4612174A1 (en) Sars-cov-2 binding antibody
WO2022140817A1 (en) Anti-viral proteases and methods of use
CN120829486A (zh) 可有效抗呼吸道rna病毒的多肽类抑制剂及其应用
CN118717729A (zh) 一种干扰素协同外泌体雾化吸入制剂及其制备方法和应用
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
CN115461356A (zh) 用于预防或治疗covid-19的肽